Adc Therapeutics SA

NYSE: ADCT
$4.97
+$0.29 (+6.2%)
Closing price April 23, 2024
ADC Therapeutics SA is a biotechnology firm focused on developing treatments for cancer. It specializes in creating antibody drug conjugates (ADCs) aimed at combating hematological malignancies and solid tumors. Its leading product, ZYNLONTA, is undergoing trials for specific lymphoma conditions. The company is also working on several other ADCs targeting various cancers, including a notable project in Hodgkin lymphoma and treatments for solid tumors and leukemia. Founded in 2011 and based in Switzerland, ADC Therapeutics collaborates with several global entities to advance its research and development efforts.
These are not the only pre-market analyst calls that are moving stocks, but these are the calls that 247WallSt.com is focusing on: ADC Telecom (NASDAQ: ADCT) and Arris (NASDAQ: ARRS) raised to Buy at...
On tonight’s MAD MONEY on CNBC, Jim Cramer said he was sticking with his stance in finding technology companies that are either oversold or overlooked in the current market malaise where he...
These are not at all the only analyst calls that 247WallSt.com is looking at today in an active negative market, but these are 10 of the more influential calls that may stand out in an otherwise...
Below is a summary of many of the top headlines and news bits from individual stocks affecting share prices in pre-market trading this Wednesday: Actuant (ATU) $0.52 EPS vs $0.48 estimate. ADC...
On tonight’s MAD MONEY on CNBC, Jim Cramer already hosted Verizon’s CEO Seidenberg and discussed the bandwidth build-outs and the great things going on in wireless and their FiOS digital...
(A) Agilent reiterated guidance after completing Stratagene buyout.(ADCT) ADC Telecom trading up 3% after posting $0.35 EPS vs $0.24 estimates.(ANN) Ann Taylor May s-s-s -4.6% versus -3.1%...